Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance

被引:22
作者
Arase, Yasuji
Suzuki, Fumitaka
Suzuki, Yoshiyuki
Saitoh, Satoshi
Kobayashi, Masahiro
Akuta, Norio
Someya, Takashi
Hosaka, Tetsuya
Sezaki, Hitomi
Sato, Junko
Kobayashi, Mariko
Ikeda, Kenji
Kumada, Hiromitsu
机构
[1] Toranomon Gen Hosp, Dept Gastroenterol, Minato Ku, Tokyo 1058470, Japan
[2] Toranomon Gen Hosp, Hepat Res Unit, Tokyo 1058470, Japan
关键词
chronic hepatitis B; hepatitis B virus DNA; seroclearance; hepatitis B surface antigen;
D O I
10.1159/000098958
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objects: The aim of this study was to elucidate the presence of serum hepatitis B virus (HBV) DNA at a prolonged time after seroclearance of hepatitis B surface antigen ( HBsAg). Methods: Seventy Japanese patients who had been observed for 1 5 years after HBsAg seroclearance were included in this study. Anti-HBs, anti-HBe and anti-HBc antibodies were measured 0, 5 and 10 years after HBsAg seroclearance. Serum HBV DNA was measured using nested polymerase chain reaction (PCR) at 0, 5 and 10 years after HBsAg seroclearance. The PCR detection of serum HBV DNA using the X gene and core gene primers was done. The HBV DNA was regarded as positive when PCR detection of HBV DNA using either or both the X gene and core gene primers was positive. A multivariate regression analysis was used to assess the factors contributing to the positivity of serum HBV DNA 5 years after HBsAg seroclearance: the factors examined included age, gender, histological findings, HBV genotype, aminotransferase, total protein and interferon administration. Results: The titers of 200-fold diluted serum anti-HBc were 6.5 +/- 4.0 at 0 year after HBsAg seroclearance, 1.8 +/- 1.4 at 5 years and 0.9 +/- 0.7 at 10 years. The titers of 200-fold diluted serum anti-HBc decreased 5 and 10 years after HBsAg seroclearance with statistical significance. The positive rate of HBV DNA by the nested PCR was 71.4% (50/70) at 0 year after HBsAg seroclearance, 21.4% (15/70) at 5 years and 14.3% (3/21) at 10 years. However, there were no significant factors contributing to the positivity of serum HBV DNA 5 years after HBsAg seroclearance. Conclusion: Our results suggest that serum HBV DNA disappears with an incidence of 10-20% 5 and 10 years after HBsAg seroclearance.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 22 条
[1]   Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance [J].
Ahn, SH ;
Park, YN ;
Park, JY ;
Chang, HY ;
Lee, JM ;
Shin, JE ;
Han, KH ;
Park, C ;
Moon, YM ;
Chon, CY .
JOURNAL OF HEPATOLOGY, 2005, 42 (02) :188-194
[2]  
Arase Y, 1999, AM J GASTROENTEROL, V94, P3304, DOI 10.1111/j.1572-0241.1999.01542.x
[3]   PERSISTENCE OF HEPATITIS-B VIRAL-DNA AFTER SEROLOGICAL RECOVERY FROM HEPATITIS-B VIRUS-INFECTION [J].
BLUM, HE ;
LIANG, TJ ;
GALUN, E ;
WANDS, JR .
HEPATOLOGY, 1991, 14 (01) :56-62
[4]   Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection [J].
Chen, YC ;
Sheen, IS ;
Chu, CM ;
Liaw, YF .
GASTROENTEROLOGY, 2002, 123 (04) :1084-1089
[5]  
CHUNG HT, 1995, HEPATOLOGY, V22, P25, DOI 10.1016/0270-9139(95)90348-8
[6]   THE NATURAL-HISTORY OF ASYMPTOMATIC HEPATITIS-B SURFACE-ANTIGEN CARRIERS [J].
DEFRANCHIS, R ;
MEUCCI, G ;
VECCHI, M ;
TATARELLA, M ;
COLOMBO, M ;
DELNINNO, E ;
RUMI, MG ;
DONATO, MF ;
RONCHI, G .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :191-194
[7]   A SHORT COURSE OF PREDNISOLONE IN CHRONIC TYPE-B HEPATITIS - REPORT OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
HOOFNAGLE, JH ;
DAVIS, GL ;
PAPPAS, SC ;
HANSON, RG ;
PETERS, M ;
AVIGAN, MI ;
WAGGONER, JG ;
JONES, EA ;
SEEFF, LB .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :12-17
[8]   Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B [J].
Hsu, YS ;
Chien, RN ;
Yeh, CT ;
Sheen, IS ;
Chiou, HY ;
Chu, CM ;
Liaw, YF .
HEPATOLOGY, 2002, 35 (06) :1522-1527
[9]   Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis [J].
Huo, TI ;
Wu, JC ;
Lee, PC ;
Chau, GY ;
Lui, WY ;
Tsay, SH ;
Ting, LT ;
Chang, FY ;
Lee, SD .
HEPATOLOGY, 1998, 28 (01) :231-236
[10]   TREATMENT OF HBV REACTIVATION AFTER WITHDRAWAL OF IMMUNOSUPPRESSION [J].
LAU, JYN ;
BIRD, GLA ;
GIMSON, AES ;
ALEXANDER, GJM ;
WILLIAMS, R .
LANCET, 1991, 337 (8744) :802-802